This inventor holds 81 USPTO granted patents and 19 published patent applications and 5 EPO patents, primarily in Tumor Infiltrating Lymphocytes (CPC class C12N). Top assignees: Iovance Biotherapeutics, Inc., Lovance Biotherapeutics, Inc., University of Pittsburgh. Active years: 1999-2026.
Inventors with similar research interests:
Company Filing History:
74 out of 110 
3 out of 4 
3 out of 1,959 
Years Active: 1999-2026
Areas of Expertise:
Title: A Pioneer in Immunotherapy: Michael T. Lotze
Introduction:
Michael T. Lotze, a renowned inventor in the field of immunotherapy, hails from Pittsburgh, PA (US). With an impressive portfolio of 69 patents, Lotze has made significant contributions to the medical field, particularly in the development of novel methods for expanding and re-stimulating tumor infiltrating lymphocytes (TILs) for immunotherapy.
Latest Patents:
1. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy: Lotze's groundbreaking invention provides improved methods for expanding TILs in a closed system, leading to enhanced efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter timeframe. These advancements not only reduce microbial contamination but also lower costs, making TILs more accessible for therapeutic treatments.
2. Restimulation of cryopreserved tumor infiltrating lymphocytes: This patent discloses innovative methods for re-stimulating TIL populations, resulting in enhanced phenotype and metabolic health, paving the way for more efficacious infusion of TILs after re-stimulation. Additionally, it offers new assays for assessing TIL populations to determine their suitability for therapeutic purposes.
Career Highlights:
Lotze has made significant strides in the field of immunotherapy through his work at companies like Iovance Biotherapeutics, Inc. and Lovance Biotherapeutics, Inc. His dedication to advancing cancer treatments has not gone unnoticed, as evidenced by his numerous patents and groundbreaking research in TIL expansion and re-stimulation techniques.
Collaborations:
Throughout his career, Lotze has collaborated with esteemed professionals in the field, including Seth Wardell and James Bender. Together, they have pushed the boundaries of immunotherapy and played a crucial role in revolutionizing cancer treatment strategies.
Conclusion:
In conclusion, Michael T. Lotze stands out as a pioneering figure in the field of immunotherapy, with a remarkable track record of innovation and groundbreaking research. His contributions have not only advanced medical science but also offered new hope to patients battling cancer. Lotze's dedication to improving TIL-based therapies is truly inspiring and continues to shape the future of cancer treatment.